Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Atlanta, Georgia 30322


Patients with kidney failure on dialysis can be successfully transplanted. However, many of them do not attain a normal kidney function and/or present a slow deterioration of kidney function after transplantation. As a consequence, they can develop an endocrine disorder called hyperparathyroidism, which can cause bone disease and a high risk of bone fractures. In spite of the known bone disease and hyperparathyroidism, there is no well defined treatment for these patients. Moreover, kidney transplant recipients present a higher mortality rate compared to the general population, and the principal cause of death is cardiovascular disease. Dialysis patients are known to have extensive cardiovascular calcifications and increased vascular stiffness, and these factors have been closely associated with cardiovascular mortality. The effect of vitamin D on bone health is well known in the general population. Many studies showed a reduction in fracture rate in post-menopausal women and older men receiving vitamin D and calcium supplements. Vitamin D analogues are also commonly used to treat hyperparathyroidism in dialysis patients. Finally, vitamin D has been suggested to have beneficial effects on the cardiovascular system and to reduce mortality in dialysis patients. Hectorol® is a vitamin D analog which has been demonstrated to effectively treat hyperparathyroidism in dialysis and pre-dialysis patients. The effects of vitamin D supplementation on bone disease, hyperparathyroidism and cardiovascular function in kidney transplant recipients have not been properly studied. Whether Hectorol® therapy helps reducing the severity of bone disease and improving vascular function in kidney transplant recipients is still unknown. We plan to study the cardiovascular and bone effects of Hectorol® in 100 kidney transplant recipients followed at our Transplant Clinic. We will screen kidney transplant patients for kidney transplant dysfunction and hyperparathyroidism. The study medication will be given to 50 patients. The other 50 patients will continue to be treated with the actual standard of care at our Transplant Clinic. We will follow these patients for 18 months and monitor laboratory values, bone density, vascular calcification and stiffness to detect any effect of Hectorol® compared to the actual standard of care.


Inclusion Criteria: - Kidney transplant recipient > 18 year/old with reduced and stable kidney function (estimated GFR 25-60 ml/min/1.73m2) - iPTH levels between 120 and 500 pg/ml - Stable immunosuppressive therapy (5-10 mg Prednisone/day, stable dosage of calcineurin inhibitors, or other immunosuppressive agents for at least 6 months) Exclusion Criteria: - Recent rejection episode (< 3 months) - One of the following: baseline estimated GFR>60 ml/min/1.73m2 or <25 ml/min/1.73m2, albumin-corrected Ca>9.5 mg/dl or serum phosphorus >4.6 mg/dl. - Recipients of dual transplant organs with exception of kidney-pancreas - Patients already receiving treatment with Vitamin D analogues - Severe peripheral vascular disease or coronary artery disease - History of previous parathyroidectomy - Current alcohol or drug abuse - Pregnant or nursing woman or female of child-bearing age not receiving contraception - Other comorbidities that in the opinion of the investigators would reduce expected patient's survival and preclude study completion - Medications that could interfere with Hectorol® metabolism



Primary Contact:

Principal Investigator
Paolo Raggi and Antonio Guasch, MDs
Emory University

Paolo Raggi, MD
Phone: 404-778-5414
Email: praggi@emory.edu

Backup Contact:

Email: aguasch@emory.edu
Antonio Guasch, MD
Phone: 404-727-3959

Location Contact:

Atlanta, Georgia 30322
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.